CompletedNCT03393026
A Study of Lurasidone HCl in Subjects With Schizophrenia
Researchers studied Lurasidone, tracking side effects to assess safety in people with schizophrenia.
Medication studyAges 20–75Taiwan
Understand this study
What did researchers investigate?
Researchers studied Lurasidone, tracking side effects to assess safety in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 20 years to 75 years. Other eligibility criteria applied.
- Listed locations
- Taipei and 1 more locationSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: January 3, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 54
- Sponsor
- Standard Chem. & Pharm. Co., Ltd.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Taiwan
- Age range
- From 20 Years to 75 Years
- Official registry ID
- NCT03393026
- Official title
Show the full official title
A Multi-Center, Open-Label, Single Arm and Flexible Dose Study of the Effectiveness and Safety of Oral Use Lurasidone HCl Tablet (LATUDA®) for 40-160 mg/Day in Subjects With Schizophrenia
Get this study by email
Recruitment & locations
CompletedTaipei
Questions about this study
What did researchers investigate?
Researchers studied Lurasidone, tracking side effects to assess safety in people with schizophrenia.
Who is behind this study?
The study sponsor is Standard Chem. & Pharm. Co., Ltd.
Did this study involve medication?
Yes. The study involved medication, including Lurasidone.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 20 years to 75 years. Other eligibility criteria applied.
